AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca is conducting a study titled ‘Positioning, Utilization and Effectiveness of Osimertinib in First Line in Real-life Therapeutic Strategy in France’ to evaluate the effectiveness of osimertinib in treating patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) with activating EGFR mutations. The study aims to provide insights into treatment patterns, overall survival, and quality of life over a 36-month period.
The intervention being tested is the drug osimertinib, which is used as a first-line treatment for NSCLC patients with specific genetic mutations. The purpose of this drug is to improve patient outcomes by targeting and inhibiting the growth of cancer cells.
This observational study employs a multicenter design, combining a cross-sectional survey and a prospective cohort approach. It does not involve random allocation or masking, focusing instead on real-world data collection to understand patient experiences and outcomes.
The study began on May 12, 2021, with an expected primary completion date in 2025. The last update was submitted on July 22, 2025. These dates are crucial as they provide a timeline for data collection and analysis, impacting the study’s findings and subsequent reporting.
The update on this study could influence AstraZeneca’s stock performance by potentially enhancing investor confidence if osimertinib proves effective. It also positions AstraZeneca competitively within the oncology market, particularly against other companies developing similar treatments for NSCLC.
The study is ongoing, with further details available on the ClinicalTrials portal.